Effect of Intravitreal Injection of Aflibercept on Cardiovascular Risk Parameters in Patients with Neovascular Age-Related Macular Degeneration.
Constantinos D GeorgakopoulosAthina PallikariPanagiotis PlotasKonstantinos KagkelarisStylianos MastronikolisMaria PlotaAndreas EmmanuilOlga E MakriPublished in: Current reviews in clinical and experimental pharmacology (2022)
According to our study, the administration of a single dose of aflibercept in eyes with neovascular age-related macular degeneration does not seem to affect the evaluated biomarkers that are related to cardiovascular disease.